Not indicated for use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
February 2026: The UK Medicines and Healthcare Products Regulatory Agency (MHRA) updated product information regarding the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
The UK MHRA advises that patients taking semaglutide who notice a change in their eyesight, such as sudden impairment to their vision, or if their eyesight gets worse very quickly in one or both eyes, should urgently attend eye casualty (if available in the area) or A&E.
An oral formulation of semaglutide and sodium salcaprozate (an intestinal permeation enhancer) is available in the United States and Europe.
